Cargando…
YAP/TAZ activation predicts clinical outcomes in mesothelioma and is conserved in in vitro model of driver mutations
The Hippo signalling pathway is dysregulated across a wide range of cancer types and, although driver mutations that directly affect the core Hippo components are rare, a handful is found within pleural mesothelioma (PM). PM is a deadly disease of the lining of the lung caused by asbestos exposure....
Autores principales: | Cunningham, Richard, Jia, Siyang, Purohit, Krishna, Salem, Omar, Hui, Ning Sze, Lin, Yue, Carragher, Neil O., Hansen, Carsten Gram |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899629/ https://www.ncbi.nlm.nih.gov/pubmed/36740402 http://dx.doi.org/10.1002/ctm2.1190 |
Ejemplares similares
-
AR activates YAP/TAZ differentially in prostate cancer
por: Salem, Omar, et al.
Publicado: (2023) -
The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer
por: Cunningham, Richard, et al.
Publicado: (2022) -
Hippo-Yap/Taz signalling in zebrafish regeneration
por: Riley, Susanna E., et al.
Publicado: (2022) -
PERCC1, a new member of the Yap/TAZ/FAM181 transcriptional co-regulator family
por: Sanchez-Pulido, Luis, et al.
Publicado: (2022) -
Dropwort-induced metabolic reprogramming restrains YAP/TAZ/TEAD oncogenic axis in mesothelioma
por: Pulito, Claudio, et al.
Publicado: (2019)